Abstracts tagged "Scleroderma"

Abstract Number: 2499 • ACR Convergence 2025
Concomitant Anti-Ro/SSA Antibodies in Systemic Sclerosis Patients is Associated with Risks Beyond Dryness
Rachael Gordon¹, Leah Wunsch², Maureen Lauffoon¹, Thomas Medsger, Jr³ and Robyn Domsic¹, ¹University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, Verona, PA
Background/Purpose: Sjogren’s disease (SjD) is a common systemic autoimmune disorder characterized by progressive inflammation of the exocrine glands, resulting in dry eyes and dry mouth.…
Abstract Number: 1871 • ACR Convergence 2025
Examining the impact of ETV2 on altered endothelial phenotype in systemic sclerosis
Elio Carmona¹, Alyssa Rosek², Neha Khanna², Dinesh Khanna³, Amr Sawalha⁴ and Pei-Suen Tsou³, ¹Division of Pediatric Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA, Pittsburgh, ²Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, ³University of Michigan, Ann Arbor, MI, ⁴University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Our prior research demonstrated that epigenetic modifications are central to the pathogenesis of scleroderma (SSc)1. Using ATAC-seq, we found that chromatin accessibility was significantly…
Abstract Number: 1554 • ACR Convergence 2025
Demographic, Clinical, and Mortality Trends in Scleroderma Patients with Gastric Antral Vascular Ectasia (GAVE): A National Inpatient Analysis
Akanksha Sharma¹, Veera Durga Vaishnavi Kurra² and Neev Mehta³, ¹UPMC Mercy hospital, Pittsburgh, PA, Pittsburgh, PA, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Lahey Hospital and Medical Center, Burlington, MA
Background/Purpose: Gastric antral vascular ectasia (GAVE), commonly known as “watermelon stomach,” is a rare but potentially severe gastrointestinal manifestation in systemic sclerosis (SSc). Despite its…
Abstract Number: 0699 • ACR Convergence 2025
A Retrospective Comparison of Transplant Outcomes in Patients with and without Systemic Sclerosis
Lilit Grigoryan, Sumbal Wajid, Giovanni Faddoul and Swati Mehta, Albany medical center, Albany, NY
Background/Purpose: Scleroderma renal crisis (SRC) is one of the life threatening complications of systemic sclerosis (SSc). Up to 20-50% require long term dialysis and subsequently…
Abstract Number: 0245 • ACR Convergence 2025
Predictors of Arterial Stiffness in Connective Tissue Diseases: Insights from the Lupus Extended Autoimmune Phenotype (LEAP) Cohort Study
cristiana Sieiro¹, Sarah Dyball², Ellen Bruce³, Ben Parker⁴ and Ian Bruce⁵, ¹Univrsity of Manchester, Manchester, United Kingdom, ²University of Manchester, Manchester, United Kingdom, ³Manchester University NHS FT, The Kellgren Centre of Rheumatology, Manchester, United Kingdom, Manchester, ⁴NIHR Manchester CRF, Manchester Royal Infirmary, Manchester, United Kingdom, ⁵Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen's University, Belfast, Manchester, United Kingdom
Background/Purpose: Connective tissue diseases (CTDs), including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and Sjögren’s disease (SjD), are associated with an increased risk of cardiovascular…
Abstract Number: 2497 • ACR Convergence 2025
Unraveling the Complexity of Interferon Responses in Peripheral Blood Mononuclear Cells in Systemic Sclerosis at Single-Cell Resolution
Pietro Bearzi¹, Elena Pachera², Astrid Hofman³, Laura Much⁴, Lumeng Li¹, Kristina Bürki³, Cosimo Bruni⁵, Mike Becker⁶, Anna-Maria Hoffmann-Vold⁷, Roberto Giacomelli⁸ and Oliver Distler⁹, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zürich, Switzerland, ²University Hospital Zurich, Zurich, Switzerland, ³Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, ⁴Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁵University of Zurich, Zurich, Switzerland, ⁶Dept. of Rheumatology, University Hospital Zurich, Zürich, Switzerland, ⁷Oslo University Hospital, Oslo, Norway, ⁸i) Clinical and Research Section of Rheumatology and Clinical Immunology, Fondazione Policlinico Campus Biomedico; ii) Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome "Campus Bio-Medico", Rome, Italy, ⁹Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: Autoimmunity is a hallmark of SSc pathogenesis. Emerging evidence suggests that interferon (IFN) signaling plays a role in predicting SSc patients at risk of…
Abstract Number: 1870 • ACR Convergence 2025
Paracrine WNT Signaling Modulates Profibrotic Macrophage Metabolic Activation in Systemic Sclerosis
emily Morris¹, Helen Jarnagin¹, Chen-Yu Wang¹, Michael Whitfield² and Patricia Pioli³, ¹Dartmouth College, Lebanon, NH, ²Geisel School of Medicine, Lebanon, NH, ³Geisel School of Medicine at Dartmouth, Lebanon, NH
Background/Purpose: An immune fibrotic axis consisting of activated macrophages (MØs) and fibroblasts has been identified in autoimmune systemic sclerosis (SSc) that drives disease across affected…
Abstract Number: 1297 • ACR Convergence 2025
Biologic Therapy for Refractory Juvenile Scleroderma: a retrospective case-series from a single tertiary care center in Saudi Arabia.
MUNIRA ALMARRI, Deena Alwakeel, Abdulaziz Alrowais and Abdulrahman Asiri, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
Background/Purpose: Scleroderma is autoimmune disease that may result in changes to the skin, blood vessels, muscles, and internal organs. It can be either Localized Scleroderma…
Abstract Number: 0698 • ACR Convergence 2025
A Retrospective Comparison of Transplant Outcomes with Different Induction Methods and Maintenance Prednisone in Systemic Sclerosis Patients
Lilit Grigoryan, Sumbal Wajid, Giovanni Faddoul and Swati Mehta, Albany medical center, Albany, NY
Background/Purpose: Systemic sclerosis (SSc) or scleroderma is a rare systemic autoimmune disease with multiple organ involvement. Renal involvement in SSc remains a significant concern, with…
Abstract Number: 0224 • ACR Convergence 2025
Improving Adherence to Pulmonary Hypertension Screening in Systemic Sclerosis Patients: Post-Intervention Analysis
John Hickernell¹ and Zineb Aouhab², ¹Loyola Univeristy Medical Center, Chicago, IL, ²Loyola University Medical Center, Oak Brook, IL
Background/Purpose: Annual screening for pulmonary hypertension (PH) in patients with Systemic Sclerosis (SSc) reduces mortality. The American College of Radiology, European Society of Cardiology/European Respiratory…
Abstract Number: 2495 • ACR Convergence 2025
IL-6/STAT3 Signaling is Central for Chemokine Production in E2-Induced Dermal Inflammation
Nicolas Ancona¹, Yucui Li², Ludivine Renaud³, Carol Feghali-Bostwick³ and DeAnna Baker Frost³, ¹MUSC Rheumatology & Immunology, Charleston, SC, ²Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi, Medical University Taiyuan, Shanxi, China (People's Republic), ³Medical University of South Carolina, Charleston, SC
Background/Purpose: Scleroderma (SSc) is an autoimmune disease characterized by dermal inflammation and fibrosis. Patients with SSc have high systemic levels of estradiol (E2), a form…
Abstract Number: 1866 • ACR Convergence 2025
Elucidating gastric pathology in systemic sclerosis using single-cell RNA sequencing
kristina clark¹, Moustafa Attar², Matthias Friedrich³, Charles Murray⁴, Alexander Clarke² and Christopher Denton⁵, ¹Kennedy Institute of Rheumatology, University of Oxford, London, United Kingdom, ²Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ³Translational Gastroenterology Unit, University of Oxford, Oxford, United Kingdom, ⁴Royal Free Hospital NHS Trust, London, United Kingdom, ⁵University College London, UK, London, United Kingdom
Background/Purpose: Gastrointestinal (GI) involvement in systemic sclerosis (SSc) affects over 90% of patients and represents a large clinical burden and unmet need. Unlike the skin…
Abstract Number: 1291 • ACR Convergence 2025
Gastrointestinal Tract Involvement in Juvenile Systemic Sclerosis: Results from an International Scoping Review of Outcome Measures
Lauren Robinson¹, Lusine Ambartsumyan², Emily Willis³, Aybuke Gunalp⁴, Simone Appenzeller⁵, Ozgur Kasapcopur⁶, Sarah Ishaq⁷, Natalia Vasquez Canizares⁸ and Suzanne Li⁹, ¹Hospital for Special Surgery, New York, NY, ²Seattle Children's Hospital, Seattle, WA, ³Royal Manchester Children's Hospital, Manchester, United Kingdom, ⁴Cerrahpasa Medicine School, Cerrahpasa, Istanbul, Turkey, ⁵Unicamp, Campinas, São Paulo, Brazil, ⁶Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, ⁷Osteopathic Medicine , Touro College of Osteopathic Medicine, New York, NY, ⁸Children's Hospital at Montefiore, New York, NY, ⁹Joseph M. Sanzari Children's Hospital and Hackensack Meridian School of Medicine, Hackensack, NJ

Background/Purpose: Gastrointestinal (GI) tract involvement is nearly universal in patients with systemic sclerosis (SSc) leading to significant morbidity and mortality. In a North American juvenile…
Abstract Number: 0695 • ACR Convergence 2025
Global Longitudinal, Circumferential, and Radial Strain in Systemic Sclerosis Patients with Left Ventricular Dysfunction
Jennifer Elise Abdalla¹, Yuichiro Okushi², Zoran Popovic², Heba Wassif² and Soumya Chatterjee³, ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic, Cleveland, ³Cleveland Clinic, Richmond Heights, OH
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune rheumatologic disease characterized by fibrosis and vascular complications, which significantly impact various organs, including the heart. Cardiac…
Abstract Number: 0161 • ACR Convergence 2025
Risk Factors and Clinical Predictors of Lung Cancer in Systemic Sclerosis: A Matched Case-Control Study from a Michigan Cohort
Madiha Naqsh Siddiqui¹, Yen Chen¹, Rosemary Gedert², Suiyuan Huang², Dinesh Khanna² and John Varga², ¹University of Michigan, Ann Arbor, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Malignancies are one of the leading causes of non-systemic sclerosis-related mortality in patients with systemic sclerosis (SSc)1, with lung cancer being the most common…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].